Top

Published in:

27-12-2023 | Smelling Disorder | Original Communication

Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease

Authors: Ruidan Wang, Tenghong Lian, Mingyue He, Peng Guo, Shuyang Yu, Lijun Zuo, Yang Hu, Wei Zhang

Published in: Journal of Neurology | Issue 4/2024

Abstract

This study aimed to investigate clinical features, influencing factors and neurobiochemical mechanisms of olfactory dysfunction (OD) in Parkinson disease (PD). Total 39 patients were divided into the PD with OD (PD–OD) and PD with no OD (PD–nOD) groups according to overall olfactory function, including threshold, discrimination and identification, assessed by Sniffin’ Sticks test. Motor function and non-motor symptoms were rated by multiple scales. Dopamine, acetylcholine, norepinephrine and 5-hydroxytryptamine levels in cerebrospinal fluid (CSF) were measured. We found that the PD–OD group showed significantly lower score of Montreal Cognitive Assessment Scale, higher scores of rapid eye movement sleep behavior disorder (RBD) Screening Questionnaire and Epworth Sleepiness Scale than the PD–nOD group (p < 0.05). RBD Screening Questionnaire score was independently associated with the scores of overall olfactory function and discrimination (p < 0.05). Dopamine and acetylcholine levels in CSF from the PD–OD group was significantly lower than that from the PD–nOD group (p < 0.05). Dopamine and acetylcholine levels in CSF were significantly and positively correlated with the scores of overall olfactory function, threshold, discrimination and identification in PD patients (p < 0.05). RBD Screening Questionnaire score was significantly and negatively correlated with acetylcholine level in CSF in PD patients with poor olfactory detection (p < 0.05). This investigation reveals that PD–OD is associated with cognitive impairment, probable RBD and excessive daytime sleepiness. PD–OD is correlated with the decreased levels of dopamine and acetylcholine in CSF. RBD is an independent influencing factor of overall olfactory function and discrimination, and the decreased acetylcholine level in CSF may be the common neurobiochemical basis of RBD and OD in PD patients.

Available only for authorised users

Berendse HW, Roos DS, Raijmakers P, Doty RL (2011) Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci 310:21–24PubMedCrossRef

Kanavou S, Pitz V, Lawton MA, Malek N, Grosset KA, Morris HR et al (2021) Comparison between four published definitions of hyposmia in Parkinson’s disease. Brain Behav 11:e2258PubMedPubMedCentralCrossRef

Chen H, Shrestha S, Huang X, Jain S, Guo X, Tranah GJ et al (2017) Olfaction and incident Parkinson disease in US white and black older adults. Neurology 89:1441–1447PubMedPubMedCentralCrossRef

Krismer F, Pinter B, Mueller C, Mahlknecht P, Nocker M, Reiter E et al (2017) Sniffing the diagnosis: olfactory testing in neurodegenerative parkinsonism. Parkinsonism Relat Disord 35:36–41PubMedCrossRef

Doty RL, Hawkes CH (2019) Chemosensory dysfunction in neurodegenerative diseases. Handb Clin Neurol 164:325–360PubMedCrossRef

Shill HA, Zhang N, Driver-Dunckley E, Mehta S, Adler CH, Beach TG (2021) Olfaction in neuropathologically defined progressive supranuclear palsy. Mov Disord 36:1700–1704PubMedPubMedCentralCrossRef

Hoyles K, Sharma JC (2013) Olfactory loss as a supporting feature in the diagnosis of Parkinson’s disease: a pragmatic approach. J Neurol 260:2951–2958PubMedCrossRef

Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:968–975PubMedCrossRef

Doty RL (2012) Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 8:329–339PubMedCrossRef

10.

Haehner A, Hummel T, Reichmann H (2014) A clinical approach towards smell loss in Parkinson’s disease. J Parkinsons Dis 4:189–195PubMedCrossRef

11.

Rahayel S, Frasnelli J, Joubert S (2012) The effect of Alzheimer’s disease and Parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res 231:60–74PubMedCrossRef

12.

Lee DH, Oh JS, Ham JH, Lee JJ, Lee I, Lee PH et al (2015) Is normosmic Parkinson disease a unique clinical phenotype? Neurology 85:1270–1275PubMedCrossRef

13.

Iijima M, Kobayakawa T, Saito S, Osawa M, Tsutsumi Y, Hashimoto S et al (2011) Differences in odor identification among clinical subtypes of Parkinson’s disease. Eur J Neurol 18:425–429PubMedCrossRef

14.

Double KL, Rowe DB, Hayes M, Chan DK, Blackie J, Corbett A et al (2003) Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 60:545–549PubMedCrossRef

15.

Huisman E, Uylings HB, Hoogland PV (2004) A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson’s disease. Mov Disord 19:687–692PubMedCrossRef

16.

Jiang S, Berger S, Hu Y, Bartsch D, Tian Y (2020) Alterations of the motor and olfactory functions related to parkinson’s disease in transgenic mice with a VMAT2-deficiency in dopaminergic neurons. Front Neurosci 14:356PubMedPubMedCentralCrossRef

17.

Oh YS, Kim JS, Hwang EJ, Lyoo CH (2018) Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease. Parkinsonism Relat Disord 56:47–51PubMedCrossRef

18.

Berkowicz DA, Trombley PQ (2000) Dopaminergic modulation at the olfactory nerve synapse. Brain Res 855:90–99PubMedCrossRef

19.

Davila NG, Blakemore LJ, Trombley PQ (2003) Dopamine modulates synaptic transmission between rat olfactory bulb neurons in culture. J Neurophysiol 90:395–404PubMedCrossRef

20.

Hsia AY, Vincent JD, Lledo PM (1999) Dopamine depresses synaptic inputs into the olfactory bulb. J Neurophysiol 82:1082–1085PubMedCrossRef

21.

Sallaz M, Jourdan F (1992) Apomorphine disrupts odour-induced patterns of glomerular activation in the olfactory bulb. NeuroReport 3:833–836PubMedCrossRef

22.

Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754PubMedPubMedCentralCrossRef

23.

Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337–341PubMedCrossRef

24.

Song S, Wang Q, Jiang L, Oyarzabal E, Riddick NV, Wilson B et al (2019) Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions. Brain Behav Immun 81:374–387PubMedPubMedCentralCrossRef

25.

Huot P, Fox SH, Brotchie JM (2011) The serotonergic system in Parkinson’s disease. Prog Neurobiol 95:163–212PubMedCrossRef

26.

Morais LH, Hara DB, Bicca MA, Poli A, Takahashi RN (2018) Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson’s disease. Behav Pharmacol 29:199–210PubMedCrossRef

27.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601PubMedCrossRef

28.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653PubMedCrossRef

29.

Rumeau C, Nguyen DT, Jankowski R (2016) How to assess olfactory performance with the Sniffin’ Sticks test^(®). Eur Ann Otorhinolaryngol Head Neck Dis 133:203–206PubMedCrossRef

30.

Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T (2019) Updated Sniffin’ sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol 276:719–728PubMedCrossRef

31.

Hummel T, Kobal G, Gudziol H, Mackay-Sim A (2007) Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264:237–243PubMedCrossRef

32.

Wen HB, Zhang ZX, Niu FS, Li L (2008) The application of Montreal cognitive assessment in urban Chinese residents of Beijing. Zhonghua Nei Ke Za Zhi 47:36–39PubMed

33.

Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745PubMedPubMedCentralCrossRef

34.

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699PubMedCrossRef

35.

Starkstein SE (2012) Apathy in Parkinson’s disease: diagnostic and etiological dilemmas. Mov Disord 27:174–178PubMedCrossRef

36.

Mele B, Merrikh D, Ismail Z, Goodarzi Z (2019) Detecting apathy in individuals with Parkinson’s disease: a systematic review. J Parkinsons Dis 9:653–664PubMedCrossRef

37.

Williams JB (2001) Standardizing the Hamilton depression rating scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci 251(Suppl 2):Ii6-12PubMedCrossRef

38.

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedCrossRef

39.

Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH (2007) The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 22:2386–2393PubMedCrossRef

40.

Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B et al (2010) Scales to assess sleep impairment in Parkinson’s disease: critique and recommendations. Mov Disord 25:2704–2716PubMedCrossRef

41.

Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540–545PubMedCrossRef

42.

Johns MW (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9:5–11PubMedCrossRef

43.

Walters AS, Frauscher B, Allen R, Benes H, Chaudhuri KR, Garcia-Borreguero D et al (2014) Review of severity rating scales for restless legs syndrome: critique and recommendations. Mov Disord Clin Pract 1:317–324PubMedPubMedCentralCrossRef

44.

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1123PubMedCrossRef

45.

Herlofson K, Larsen JP (2002) Measuring fatigue in patients with Parkinson’s disease—the Fatigue Severity Scale. Eur J Neurol 9:595–600PubMedCrossRef

46.

Guo P, Wang RD, Lian TH, Ding DY, Zhang YN, Zhang WJ et al (2020) Olfactory dysfunction and its association with neuropathologic proteins in cerebrospinal fluid from patients with Parkinson disease. Front Aging Neurosci 12:594324PubMedPubMedCentralCrossRef

47.

Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA et al (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15:490–494PubMedCrossRef

48.

Trentin S, Fraiman de Oliveira BS, Ferreira Felloni Borges Y, de Mello Rieder CR (2022) Systematic review and meta-analysis of Sniffin Sticks Test performance in Parkinson’s disease patients in different countries. Eur Arch Otorhinolaryngol 279:1123–1145PubMedCrossRef

49.

Doty RL (2012) Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis 46:527–552PubMedCrossRef

50.

Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM et al (2016) Position paper on olfactory dysfunction. Rhinology 56:1–30PubMed

51.

Doty RL, Wylie C, Potter M, Beston R, Cope B, Majam K (2019) Clinical validation of the olfactory detection threshold module of the Snap & Sniff^® olfactory test system. Int Forum Allergy Rhinol 9:986–992PubMedCrossRef

52.

Boesveldt S, Verbaan D, Knol DL, Visser M, van Rooden SM, van Hilten JJ et al (2008) A comparative study of odor identification and odor discrimination deficits in Parkinson’s disease. Mov Disord 23:1984–1990PubMedCrossRef

53.

Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S et al (2012) Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: a 3 year longitudinal study. Brain 135:161–169PubMedCrossRef

54.

Morley JF, Weintraub D, Mamikonyan E, Moberg PJ, Siderowf AD, Duda JE (2011) Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson’s disease. Mov Disord 26:2051–2057PubMedPubMedCentralCrossRef

55.

Baba T, Takeda A, Kikuchi A, Nishio Y, Hosokai Y, Hirayama K et al (2011) Association of olfactory dysfunction and brain. Metabolism in Parkinson’s disease. Mov Disord 26:621–628PubMedCrossRef

56.

Masala C, Solla P, Liscia A, Defazio G, Saba L, Cannas A et al (2018) Correlation among olfactory function, motors’ symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson’s disease. J Neurol 265:1764–1771PubMedCrossRef

57.

Fang TC, Chang MH, Yang CP, Chen YH, Lin CH (2021) The association of olfactory dysfunction with depression, cognition, and disease severity in Parkinson’s disease. Front Neurol 12:779712PubMedPubMedCentralCrossRef

58.

Verbaan D, Boesveldt S, van Rooden SM, Visser M, Marinus J, Macedo MG et al (2008) Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics? Neurology 71:1877–1882PubMedCrossRef

59.

Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T (2010) Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol 32:1062–1067PubMedCrossRef

60.

Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73:273–278PubMedCrossRef

61.

Takeda A, Baba T, Kikuchi A, Hasegawa T, Sugeno N, Konno M et al (2014) Olfactory dysfunction and dementia in Parkinson’s disease. J Parkinsons Dis 4:181–187PubMedCrossRef

62.

Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X (2014) Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Disord 29:1205–1208PubMedPubMedCentralCrossRef

63.

Cramer CK, Friedman JH, Amick MM (2010) Olfaction and apathy in Parkinson’s disease. Parkinsonism Relat Disord 16:124–126PubMedCrossRef

64.

Hong JY, Sunwoo MK, Ham JH, Lee JJ, Lee PH, Sohn YH (2015) Apathy and olfactory dysfunction in early Parkinson’s disease. J Mov Disord 8:21–25PubMedPubMedCentralCrossRef

65.

Solla P, Masala C, Liscia A, Piras R, Ercoli T, Fadda L et al (2020) Sex-related differences in olfactory function and evaluation of possible confounding factors among patients with Parkinson’s disease. J Neurol 267:57–63PubMedCrossRef

66.

Martinez-Nunez AE, Latack K, Situ-Kcomt M, Mahajan A (2022) Olfaction and apathy in early idiopathic Parkinson’s disease. J Neurol Sci 439:120314PubMedCrossRef

67.

Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y et al (2014) REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry 85:560–566PubMedCrossRef

68.

Jin H, Zhang JR, Shen Y, Liu CF (2017) Clinical significance of REM sleep behavior disorders and other non-motor symptoms of Parkinsonism. Neurosci Bull 33:576–584PubMedPubMedCentralCrossRef

69.

Schenck CH, Boeve BF, Mahowald MW (2013) Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 14:744–748PubMedCrossRef

70.

Kim YE, Jeon BS (2014) Clinical implication of REM sleep behavior disorder in Parkinson’s disease. J Parkinsons Dis 4:237–244PubMedCrossRef

71.

Lyu Z, Zheng S, Zhang X, Mai Y, Pan J, Hummel T et al (2021) Olfactory impairment as an early marker of Parkinson’s disease in REM sleep behaviour disorder: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 92:271–281PubMedCrossRef

72.

Shin JH, Lee JY, Kim YK, Shin SA, Kim H, Nam H et al (2020) Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder. Neurology 95:e3081–e3092PubMedCrossRef

73.

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef

74.

Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W et al (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27:617–626PubMedCrossRef

75.

Mazza S, Soucy JP, Gravel P, Michaud M, Postuma R, Massicotte-Marquez J et al (2006) Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 67:1618–1622PubMedCrossRef

76.

Iranzo A, Graus F, Clover L, Morera J, Bruna J, Vilar C et al (2006) Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol 59:178–181PubMedCrossRef

77.

Ogaki K, Fujita H, Nozawa N, Shiina T, Sakuramoto H, Suzuki K (2023) Factors contributing to sleep disturbances and excessive daytime sleepiness in patients with Parkinson’s disease. Front Neurol 14:1097251PubMedPubMedCentralCrossRef

78.

Hu Y, Guo P, Lian TH, Zuo LJ, Yu SY, Liu L et al (2021) Clinical characteristics, iron metabolism and neuroinflammation: new insight into excessive daytime sleepiness in Parkinson’s disease. Neuropsychiatr Dis Treat 17:2041–2051PubMedPubMedCentralCrossRef

79.

Yang J, Lv DJ, Li LX, Wang YL, Qi D, Chen J et al (2019) Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson’s disease. Neurotoxicology 73:175–182PubMedCrossRef

80.

Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ et al (2010) A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM 103:941–952PubMedCrossRef

81.

Mundiñano IC, Caballero MC, Ordóñez C, Hernandez M, DiCaudo C, Marcilla I et al (2011) Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. Acta Neuropathol 122:61–74PubMedCrossRef

82.

Lelan F, Boyer C, Thinard R, Rémy S, Usal C, Tesson L et al (2011) Effects of human alpha-synuclein A53T–A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease. Parkinsons Dis 2011:987084PubMedPubMedCentral

83.

Yamada M, Onodera M, Mizuno Y, Mochizuki H (2004) Neurogenesis in olfactory bulb identified by retroviral labeling in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated adult mice. Neuroscience 124:173–181PubMedCrossRef

84.

Belzunegui S, San Sebastián W, Garrido-Gil P, Izal-Azcárate A, Vázquez-Claverie M, López B et al (2007) The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 61:1006–1012PubMedCrossRef

85.

Doty RL (2017) Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol 16:478–488PubMedCrossRef

86.

Ohkuma M, Kawai F, Miyachi E (2013) Acetylcholine enhances excitability by lowering the threshold of spike generation in olfactory receptor cells. J Neurophysiol 110:2082–2089PubMedCrossRef

87.

Velayudhan L, Lovestone S (2009) Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezil. J Clin Psychopharmacol 29:387–390PubMedCrossRef

88.

Zhang S, Xiao Q, Le W (2015) Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS ONE 10:e0119928PubMedPubMedCentralCrossRef

89.

Versace V, Langthaler PB, Sebastianelli L, Höller Y, Brigo F, Orioli A et al (2017) Impaired cholinergic transmission in patients with Parkinson’s disease and olfactory dysfunction. J Neurol Sci 377:55–61PubMedCrossRef

90.

Oh E, Park J, Youn J, Kim JS, Park S, Jang W (2017) Olfactory dysfunction in early Parkinson’s disease is associated with short latency afferent inhibition reflecting central cholinergic dysfunction. Clin Neurophysiol 128:1061–1068PubMedCrossRef

91.

Suzuki Y, Kiyokage E, Sohn J, Hioki H, Toida K (2015) Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb. J Comp Neurol 523:262–280PubMedCrossRef

92.

Jovanovic H, Perski A, Berglund H, Savic I (2011) Chronic stress is linked to 5-HT(1A) receptor changes and functional disintegration of the limbic networks. Neuroimage 55:1178–1188PubMedCrossRef

Title: Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease
Authors: Ruidan Wang
Tenghong Lian
Mingyue He
Peng Guo
Shuyang Yu
Lijun Zuo
Yang Hu
Wei Zhang
Publication date: 27-12-2023
Publisher: Springer Berlin Heidelberg
Keywords: Smelling Disorder
Smelling Disorder
Parkinson's Disease
Published in: Journal of Neurology / Issue 4/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12122-1

2024 ASCO Annual Meeting

Springer Medicine

Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing–remitting multiple sclerosis: a 20-year follow-up cohort

Routine outcomes and evaluation of an 8-week outpatient multidisciplinary rehabilitative therapy program for functional neurological disorder

Herbert Coddington Major (1850–1921)

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI)

Multisensory hallucinations and other unusual sensory experiences in the context of migraine: a systematic review